Evidence-based guidelines are presented on the selection and use of therapeutic products available in the UK to treat haemophilia and other hereditary bleeding disorders.

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.